VectorXcellerator Programme
Fully funded feasibility studies to support early-stage cell and gene therapy programmes, leveraging OXB’s proven inAVVate™ and LentiVector™ platforms.
VectorXcellerator is a new OXB initiative offering fully funded feasibility studies for early-stage AAV and lentiviral vector programmes.
Application info
Applications open: 9th February
Applications close: 10th April | 23:59 (GMT)
Outcome notification: 12th May
Why VectorXcellerator?
Early development decisions can have long-term implications for cell and gene therapy programmes, particularly when it comes to vector design, process development, manufacturability, and scalability.
VectorXcellerator has been created to support organisations developing promising early-stage programmes by generating feasibility-level data and technical confidence to guide next development steps, with no obligation for future commercial engagement.
What's included?
Selected programmes will receive a fully funded feasibility study leveraging OXB’s proven platforms. Scope and deliverables will be agreed prior to study initiation. Packages may include:
A typical feasibility study could include:
- Project Initiation Enabling Activities
- Cloning of the Applicant’s gene of interest into OXB genome plasmid backbone(s)
- Small-scale upstream and downstream process evaluation
- A defined set of platform analytical assays
Programme Outputs:
- Genome plasmid(s) constructed as specified
- Slide deck summarising key findings
- Viral vector samples (subject to availability and for research purposes only)
Who is VectorXcellerator designed for?
VectorXcellerator is designed to support organisations that are:
-
Advancing early-stage cell and gene therapy programmes
-
Seeking to address defined technical or feasibility questions related to viral vector development and manufacturing
-
Looking for specialised viral vector expertise to inform early development decisions
Apply today
If VectorXcellerator is a good fit for your programme, we invite you to apply by completing the application form and confidentially agreement, and submitting to vectorxcellerator@oxb.com by 10th Apr 2026 | 23:59 (GMT). Complete the form below to access the application pack.
We understand that some of the information provided by you in the application form may be of a confidential nature and therefore we have included a mutual confidentiality agreement (CDA), signed by OXB, in the application bundle. Participation in the application process will also require you to grant OXB the right to use anonymised data gathered as part of the invite for the VectorXcellerator progamme & generated during the selected feasibility studies (see clause 4 of the CDA). Before submitting your application form, please ensure the CDA is completed with your company details on the last page and signed by an authorised signatory. Due to the anticipated volume of applications, please be aware that OXB is not in a position to consider any changes to the terms of the CDA.
For questions, please contact: vectorxcellerator@oxb.com
Selection process and timeline
Applications will be reviewed by a cross-functional OXB panel with expertise in viral vector development and manufacturing.
Indicative timeline
Applications open
Applications close
Review period
Outcome notification
Due to the selective nature of the initiative, only a small number of applications will be successful.
Frequently asked questions
Disclaimer
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation.
These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.
Learn more at www.oxb.com and follow us on LinkedIn and YouTube.